Porcine Vaccines Market by Vaccine Type (Inactivated, Live Attenuated, MRNA), Disease Indication (Classical Swine Fever, Erysipelas, Porcine Reproductive And Respiratory Syndrome), End User, Route Of Administration, Technology, Dosage Form - Global Foreca
Description
The Porcine Vaccines Market was valued at USD 1.82 billion in 2024 and is projected to grow to USD 1.94 billion in 2025, with a CAGR of 6.98%, reaching USD 3.12 billion by 2032.
Framing the modern porcine vaccine ecosystem with strategic context on innovation, regulatory drivers, and operational adoption dynamics
The porcine vaccines landscape sits at the intersection of animal health innovation, supply chain resilience, and global biosecurity priorities. Recent advances in molecular platforms, manufacturing technologies, and regulatory harmonization have collectively expanded the toolkit available to veterinarians, producers, and public health stakeholders seeking to control endemic and emerging swine diseases. Simultaneously, shifts in production systems, trade policy, and consumer expectations are elevating the strategic role of vaccines as enablers of herd productivity, antimicrobial stewardship, and disease surveillance integration.
This introductory analysis synthesizes the core drivers reshaping the market for porcine vaccines, highlighting technological inflection points, evolving end-user needs, and the regulatory pressures that influence product development pathways. It frames the competitive dynamics that incumbent animal health manufacturers and agile biotech entrants must navigate, and it emphasizes the operational considerations-cold chain integrity, administration routes, and dosing formats-that determine adoption at farm level. The intent is to provide readers with a clear, concise context for the deeper thematic and tactical insights that follow, enabling executives and technical leaders to align strategic priorities with the current state of science and market expectations.
Identifying the major platform-driven, regulatory, and partnership shifts that are redefining porcine vaccine development and commercialization strategies
Over the last decade the porcine vaccine landscape has undergone transformative shifts rooted in platform diversification, precision immunology, and strategic collaborations between biotech innovators and traditional animal health companies. RNA-based technologies and recombinant approaches have moved from proof-of-concept to advanced development, compelling established manufacturers to reassess pipeline priorities and manufacturing footprints. These platform shifts have introduced new considerations for stability, cold chain logistics, and dosing paradigms, which in turn affect delivery strategies across commercial and smallholder contexts.
Concurrently, data-driven decision making and digital tools for surveillance and vaccine efficacy monitoring are reshaping how vaccine impact is measured and communicated to end users. This transition toward outcome-based metrics favors vaccines that demonstrably reduce pathogen circulation and contribute to reduced antimicrobial use, creating a competitive advantage for developers able to generate robust field data. Additionally, public-private partnerships and contract development and manufacturing organizations have become pivotal in accelerating time-to-market for novel constructs, enabling scalable production while spreading technical and financial risk. Ultimately, these shifts are realigning investment flows, regulatory engagement, and commercial go-to-market approaches across the sector.
Assessing how the 2025 United States tariff measures have pressured supply chains, sourcing strategies, and procurement choices across the porcine vaccine value chain
The imposition of tariffs by the United States in 2025 has produced a multifaceted effect on the porcine vaccines value chain, manifesting across procurement practices, supplier relationships, and inventory strategies. For manufacturers and importers, altered tariff schedules have increased the emphasis on regionalization of supply and the reassessment of sourcing for critical raw materials, adjuvants, and specialized vial components. These adjustments have, in many cases, accelerated conversations about nearshoring and the diversification of contract manufacturing partners to mitigate exposure to cross-border trade frictions.
At the farm and veterinary practice level, procurement cycles and purchasing portfolios have shifted toward vendors that can demonstrate supply continuity and flexible logistics solutions. This dynamic has created opportunities for local manufacturers and contract partners to capture nearer-term demand where international sourcing has become less predictable. Moreover, the tariff environment has prompted stakeholders to revisit inventory management policies and to invest in demand sensing and buffer strategies that preserve vaccination schedules without compromising herd health objectives. Lastly, regulatory and trade compliance functions are now more central to commercial planning, as firms balance cost pressures with the imperative to maintain uninterrupted access to essential vaccine inputs and finished products.
Comprehensive segmentation analysis linking vaccine platforms, disease targets, end-user profiles, administration routes, technologies, and dosage formats to commercialization imperatives
A nuanced understanding of segmentation illuminates product development priorities and commercialization pathways across vaccine types, disease targets, end users, administration routes, technology platforms, and dosage forms. When examining vaccines by type, inactivated constructs remain differentiated into split virus, subcellular, and whole virus formats, each offering trade-offs between immunogenicity and manufacturing complexity, while live attenuated approaches are categorized into heterologous and homologous variants that influence efficacy profiles and safety considerations. The emergence of mRNA modalities introduces distinctions between non-amplifying and self-amplifying constructs, which affect dosing strategies and cold chain requirements. Subunit vaccines are further parsed into polysaccharide and protein subunits with distinct adjuvant and conjugation needs, and virus-vectored platforms typically employ adenovirus or poxvirus backbones that drive regulatory pathways and preclinical modeling.
Disease indication segmentation highlights classical swine fever, erysipelas, porcine reproductive and respiratory syndrome, and swine influenza as priority targets that shape R&D focus and field deployment strategies. End-user segmentation differentiates commercial farms, research institutes, smallholder farms, and veterinary hospitals, each representing varying procurement sophistication, cold chain capacity, and adoption thresholds. Route of administration-intracutaneous, intramuscular, intranasal, oral, and subcutaneous-conditions product format design and training requirements for on-farm administration. Technology classification into conventional, DNA, recombinant, RNA, and virus-like particle modalities further clarifies manufacturing investments; conventional approaches split into attenuated live and killed whole, while recombinant solutions are produced via bacteria, insect cell, or yeast expression systems, each with unique yields, purification complexity, and regulatory dossiers. Dosage form segmentation into emulsion, liquid, and lyophilized formats completes the taxonomy, underlining how stability and delivery format dictate distribution and field usability. Together, these segmentation lenses inform portfolio prioritization, pricing strategies, and commercialization tactics for stakeholders across the ecosystem.
Regional implications of regulatory variance, manufacturing capacity, and supply chain resilience shaping porcine vaccine market entry and partnership strategies
Regional dynamics exert a powerful influence on regulatory pathways, manufacturing capacity, and market access strategies within the porcine vaccines landscape. In the Americas, regulatory harmonization efforts and strong private sector investment have supported robust development pipelines and advanced manufacturing capabilities, driving emphasis on scalable platforms and commercial distribution networks. Conversely, Europe, Middle East & Africa present a mosaic of regulatory environments and production capacities that require adaptive market entry strategies and an emphasis on compliance, surveillance data generation, and localized stakeholder engagement. In Asia-Pacific, intense production volumes, dense supply chains, and rising biotech investment create fertile ground for rapid adoption of novel platforms, but also demand sensitivity to export controls, intellectual property frameworks, and varying cold chain infrastructures.
Across these regions, policy priorities and trade relationships shape sourcing strategies and partnership formation. Investment in regional manufacturing hubs and cold chain enhancements has become a recurring strategic response to mitigate trade friction and to ensure vaccine availability during disease outbreaks. Moreover, collaborative research networks and public-private initiatives in certain markets accelerate the translation of scientific advances into field-ready products. Taken together, regional insights inform decisions about where to concentrate clinical programs, how to structure manufacturing alliances, and what commercial models will best align with the logistical realities and regulatory expectations of each territory.
Market leader and challenger behaviours emphasizing platform adoption, strategic alliances, and CDMO partnerships that accelerate porcine vaccine commercialization
Key company dynamics in the porcine vaccines domain reflect a balance between legacy animal health manufacturers, specialized biotechnology firms, and contract development and manufacturing providers. Established players continue to leverage broad commercial networks, scale manufacturing, and deep regulatory experience, while smaller biotech entrants introduce platform innovations and focused disease programs that can alter competitive positioning. Strategic alliances, licensing agreements, and targeted acquisitions remain primary mechanisms for incumbents to access novel technologies and to accelerate pipeline diversification without incurring the full burden of internal R&D.
Contract manufacturing organizations and specialized service providers play an increasingly central role by offering capacity for biologics production, fill-finish services, and regulatory support, enabling virtual or asset-light vaccine developers to bring products to market. Companies that demonstrate proficiency in bridging laboratory-scale proof-of-concept to commercial manufacturing, while preserving quality and regulatory compliance, command a distinct advantage. Additionally, firms that can produce rigorous field-efficacy data, manage cold chain complexity, and maintain transparent post-market surveillance programs strengthen trust with veterinarians and producers, which is essential for adoption. Competitive differentiation increasingly hinges on the ability to integrate scientific innovation with pragmatic commercialization capabilities and resilient supply chain strategies.
Practical strategic actions for companies to align manufacturing agility, partnership networks, and field evidence generation for accelerated market adoption
Industry leaders should prioritize a set of actionable moves that align scientific innovation with commercial execution to maintain a competitive edge. First, investing in platform-agnostic manufacturing flexibility will enable rapid pivoting between conventional, recombinant, RNA, and vectored constructs as regulatory and market conditions evolve, thereby reducing time-to-field for promising candidates. Second, forming targeted partnerships with contract developers and regional manufacturers can mitigate trade exposure and enhance supply continuity, supporting both commercial scale-up and emergency response capabilities. Third, committing to robust field-efficacy studies and transparent pharmacovigilance programs will strengthen credibility with veterinarians and producers, and will serve as a foundation for outcome-based value propositions tied to antibiotic stewardship and production performance.
Furthermore, leaders should refine pricing and access strategies to address heterogeneity across commercial farms, smallholder settings, and institutional buyers, while tailoring packaging and dosing formats to align with on-farm capabilities. Emphasizing training programs for diverse administration routes and investing in cold chain innovations that reduce logistical friction will broaden market reach. Finally, integrating digital tools for surveillance, traceability, and performance analytics can enhance post-market insights and create differentiated services that extend beyond the vaccine vial to deliver measurable herd health outcomes.
Transparent research approach combining expert interviews, literature synthesis, and scenario analysis to validate insights on porcine vaccine development and delivery
This research syntheses multiple methodological approaches to ensure a rigorous and transparent analysis of the porcine vaccine landscape. Primary research included structured interviews with subject matter experts spanning vaccine developers, manufacturing specialists, veterinarians, and regulatory advisors, which provided qualitative context on product development priorities and adoption barriers. Secondary research drew upon peer-reviewed literature, regulatory guidance documents, patent filings, and company disclosures to triangulate technological trends and historical program trajectories, while ensuring factual accuracy and industry relevance.
Analytical methods encompassed comparative platform assessments, lifecycle mapping from discovery to field deployment, and supply chain resilience evaluations to identify structural vulnerabilities and competitive levers. Wherever applicable, the methodology incorporated scenario analysis to stress-test strategic options against trade policy shifts, manufacturing constraints, and evolving disease pressures. The research also subjected key assumptions to peer validation through expert workshops, and documented limitations where public data were sparse, recommending targeted follow-up studies to close identified evidence gaps. This transparent approach supports confident application of the insights by technical leaders and commercial decision-makers.
Concluding synthesis highlighting the interplay of technological innovation, supply chain resilience, and evidence generation that will determine long-term vaccine impact
In conclusion, the porcine vaccine sector is at a pivotal juncture where platform innovation, supply chain strategy, and field-evidence generation collectively determine which products will achieve wide adoption and sustained impact. Technological advances offer transformative potential to address complex disease challenges, but realizing that potential depends on pragmatic alignment between manufacturing capabilities, regulatory navigation, and the operational realities of diverse end users. Stakeholders that invest in flexible manufacturing, robust surveillance, and strategic partnerships will be best positioned to convert scientific promise into durable herd health outcomes.
Moving forward, the combination of regional manufacturing resilience, outcome-focused communication to producers, and rigorous post-market evidence will differentiate successful programs. Firms that effectively integrate these elements can expect greater acceptance by veterinarians and producers, stronger relationships with regulators, and a more resilient commercial footprint in the face of trade and logistical disruptions. The collective imperative is to translate innovation into reliable, accessible vaccines that sustain productivity, animal welfare, and public trust in livestock health systems.
Note: PDF & Excel + Online Access - 1 Year
Framing the modern porcine vaccine ecosystem with strategic context on innovation, regulatory drivers, and operational adoption dynamics
The porcine vaccines landscape sits at the intersection of animal health innovation, supply chain resilience, and global biosecurity priorities. Recent advances in molecular platforms, manufacturing technologies, and regulatory harmonization have collectively expanded the toolkit available to veterinarians, producers, and public health stakeholders seeking to control endemic and emerging swine diseases. Simultaneously, shifts in production systems, trade policy, and consumer expectations are elevating the strategic role of vaccines as enablers of herd productivity, antimicrobial stewardship, and disease surveillance integration.
This introductory analysis synthesizes the core drivers reshaping the market for porcine vaccines, highlighting technological inflection points, evolving end-user needs, and the regulatory pressures that influence product development pathways. It frames the competitive dynamics that incumbent animal health manufacturers and agile biotech entrants must navigate, and it emphasizes the operational considerations-cold chain integrity, administration routes, and dosing formats-that determine adoption at farm level. The intent is to provide readers with a clear, concise context for the deeper thematic and tactical insights that follow, enabling executives and technical leaders to align strategic priorities with the current state of science and market expectations.
Identifying the major platform-driven, regulatory, and partnership shifts that are redefining porcine vaccine development and commercialization strategies
Over the last decade the porcine vaccine landscape has undergone transformative shifts rooted in platform diversification, precision immunology, and strategic collaborations between biotech innovators and traditional animal health companies. RNA-based technologies and recombinant approaches have moved from proof-of-concept to advanced development, compelling established manufacturers to reassess pipeline priorities and manufacturing footprints. These platform shifts have introduced new considerations for stability, cold chain logistics, and dosing paradigms, which in turn affect delivery strategies across commercial and smallholder contexts.
Concurrently, data-driven decision making and digital tools for surveillance and vaccine efficacy monitoring are reshaping how vaccine impact is measured and communicated to end users. This transition toward outcome-based metrics favors vaccines that demonstrably reduce pathogen circulation and contribute to reduced antimicrobial use, creating a competitive advantage for developers able to generate robust field data. Additionally, public-private partnerships and contract development and manufacturing organizations have become pivotal in accelerating time-to-market for novel constructs, enabling scalable production while spreading technical and financial risk. Ultimately, these shifts are realigning investment flows, regulatory engagement, and commercial go-to-market approaches across the sector.
Assessing how the 2025 United States tariff measures have pressured supply chains, sourcing strategies, and procurement choices across the porcine vaccine value chain
The imposition of tariffs by the United States in 2025 has produced a multifaceted effect on the porcine vaccines value chain, manifesting across procurement practices, supplier relationships, and inventory strategies. For manufacturers and importers, altered tariff schedules have increased the emphasis on regionalization of supply and the reassessment of sourcing for critical raw materials, adjuvants, and specialized vial components. These adjustments have, in many cases, accelerated conversations about nearshoring and the diversification of contract manufacturing partners to mitigate exposure to cross-border trade frictions.
At the farm and veterinary practice level, procurement cycles and purchasing portfolios have shifted toward vendors that can demonstrate supply continuity and flexible logistics solutions. This dynamic has created opportunities for local manufacturers and contract partners to capture nearer-term demand where international sourcing has become less predictable. Moreover, the tariff environment has prompted stakeholders to revisit inventory management policies and to invest in demand sensing and buffer strategies that preserve vaccination schedules without compromising herd health objectives. Lastly, regulatory and trade compliance functions are now more central to commercial planning, as firms balance cost pressures with the imperative to maintain uninterrupted access to essential vaccine inputs and finished products.
Comprehensive segmentation analysis linking vaccine platforms, disease targets, end-user profiles, administration routes, technologies, and dosage formats to commercialization imperatives
A nuanced understanding of segmentation illuminates product development priorities and commercialization pathways across vaccine types, disease targets, end users, administration routes, technology platforms, and dosage forms. When examining vaccines by type, inactivated constructs remain differentiated into split virus, subcellular, and whole virus formats, each offering trade-offs between immunogenicity and manufacturing complexity, while live attenuated approaches are categorized into heterologous and homologous variants that influence efficacy profiles and safety considerations. The emergence of mRNA modalities introduces distinctions between non-amplifying and self-amplifying constructs, which affect dosing strategies and cold chain requirements. Subunit vaccines are further parsed into polysaccharide and protein subunits with distinct adjuvant and conjugation needs, and virus-vectored platforms typically employ adenovirus or poxvirus backbones that drive regulatory pathways and preclinical modeling.
Disease indication segmentation highlights classical swine fever, erysipelas, porcine reproductive and respiratory syndrome, and swine influenza as priority targets that shape R&D focus and field deployment strategies. End-user segmentation differentiates commercial farms, research institutes, smallholder farms, and veterinary hospitals, each representing varying procurement sophistication, cold chain capacity, and adoption thresholds. Route of administration-intracutaneous, intramuscular, intranasal, oral, and subcutaneous-conditions product format design and training requirements for on-farm administration. Technology classification into conventional, DNA, recombinant, RNA, and virus-like particle modalities further clarifies manufacturing investments; conventional approaches split into attenuated live and killed whole, while recombinant solutions are produced via bacteria, insect cell, or yeast expression systems, each with unique yields, purification complexity, and regulatory dossiers. Dosage form segmentation into emulsion, liquid, and lyophilized formats completes the taxonomy, underlining how stability and delivery format dictate distribution and field usability. Together, these segmentation lenses inform portfolio prioritization, pricing strategies, and commercialization tactics for stakeholders across the ecosystem.
Regional implications of regulatory variance, manufacturing capacity, and supply chain resilience shaping porcine vaccine market entry and partnership strategies
Regional dynamics exert a powerful influence on regulatory pathways, manufacturing capacity, and market access strategies within the porcine vaccines landscape. In the Americas, regulatory harmonization efforts and strong private sector investment have supported robust development pipelines and advanced manufacturing capabilities, driving emphasis on scalable platforms and commercial distribution networks. Conversely, Europe, Middle East & Africa present a mosaic of regulatory environments and production capacities that require adaptive market entry strategies and an emphasis on compliance, surveillance data generation, and localized stakeholder engagement. In Asia-Pacific, intense production volumes, dense supply chains, and rising biotech investment create fertile ground for rapid adoption of novel platforms, but also demand sensitivity to export controls, intellectual property frameworks, and varying cold chain infrastructures.
Across these regions, policy priorities and trade relationships shape sourcing strategies and partnership formation. Investment in regional manufacturing hubs and cold chain enhancements has become a recurring strategic response to mitigate trade friction and to ensure vaccine availability during disease outbreaks. Moreover, collaborative research networks and public-private initiatives in certain markets accelerate the translation of scientific advances into field-ready products. Taken together, regional insights inform decisions about where to concentrate clinical programs, how to structure manufacturing alliances, and what commercial models will best align with the logistical realities and regulatory expectations of each territory.
Market leader and challenger behaviours emphasizing platform adoption, strategic alliances, and CDMO partnerships that accelerate porcine vaccine commercialization
Key company dynamics in the porcine vaccines domain reflect a balance between legacy animal health manufacturers, specialized biotechnology firms, and contract development and manufacturing providers. Established players continue to leverage broad commercial networks, scale manufacturing, and deep regulatory experience, while smaller biotech entrants introduce platform innovations and focused disease programs that can alter competitive positioning. Strategic alliances, licensing agreements, and targeted acquisitions remain primary mechanisms for incumbents to access novel technologies and to accelerate pipeline diversification without incurring the full burden of internal R&D.
Contract manufacturing organizations and specialized service providers play an increasingly central role by offering capacity for biologics production, fill-finish services, and regulatory support, enabling virtual or asset-light vaccine developers to bring products to market. Companies that demonstrate proficiency in bridging laboratory-scale proof-of-concept to commercial manufacturing, while preserving quality and regulatory compliance, command a distinct advantage. Additionally, firms that can produce rigorous field-efficacy data, manage cold chain complexity, and maintain transparent post-market surveillance programs strengthen trust with veterinarians and producers, which is essential for adoption. Competitive differentiation increasingly hinges on the ability to integrate scientific innovation with pragmatic commercialization capabilities and resilient supply chain strategies.
Practical strategic actions for companies to align manufacturing agility, partnership networks, and field evidence generation for accelerated market adoption
Industry leaders should prioritize a set of actionable moves that align scientific innovation with commercial execution to maintain a competitive edge. First, investing in platform-agnostic manufacturing flexibility will enable rapid pivoting between conventional, recombinant, RNA, and vectored constructs as regulatory and market conditions evolve, thereby reducing time-to-field for promising candidates. Second, forming targeted partnerships with contract developers and regional manufacturers can mitigate trade exposure and enhance supply continuity, supporting both commercial scale-up and emergency response capabilities. Third, committing to robust field-efficacy studies and transparent pharmacovigilance programs will strengthen credibility with veterinarians and producers, and will serve as a foundation for outcome-based value propositions tied to antibiotic stewardship and production performance.
Furthermore, leaders should refine pricing and access strategies to address heterogeneity across commercial farms, smallholder settings, and institutional buyers, while tailoring packaging and dosing formats to align with on-farm capabilities. Emphasizing training programs for diverse administration routes and investing in cold chain innovations that reduce logistical friction will broaden market reach. Finally, integrating digital tools for surveillance, traceability, and performance analytics can enhance post-market insights and create differentiated services that extend beyond the vaccine vial to deliver measurable herd health outcomes.
Transparent research approach combining expert interviews, literature synthesis, and scenario analysis to validate insights on porcine vaccine development and delivery
This research syntheses multiple methodological approaches to ensure a rigorous and transparent analysis of the porcine vaccine landscape. Primary research included structured interviews with subject matter experts spanning vaccine developers, manufacturing specialists, veterinarians, and regulatory advisors, which provided qualitative context on product development priorities and adoption barriers. Secondary research drew upon peer-reviewed literature, regulatory guidance documents, patent filings, and company disclosures to triangulate technological trends and historical program trajectories, while ensuring factual accuracy and industry relevance.
Analytical methods encompassed comparative platform assessments, lifecycle mapping from discovery to field deployment, and supply chain resilience evaluations to identify structural vulnerabilities and competitive levers. Wherever applicable, the methodology incorporated scenario analysis to stress-test strategic options against trade policy shifts, manufacturing constraints, and evolving disease pressures. The research also subjected key assumptions to peer validation through expert workshops, and documented limitations where public data were sparse, recommending targeted follow-up studies to close identified evidence gaps. This transparent approach supports confident application of the insights by technical leaders and commercial decision-makers.
Concluding synthesis highlighting the interplay of technological innovation, supply chain resilience, and evidence generation that will determine long-term vaccine impact
In conclusion, the porcine vaccine sector is at a pivotal juncture where platform innovation, supply chain strategy, and field-evidence generation collectively determine which products will achieve wide adoption and sustained impact. Technological advances offer transformative potential to address complex disease challenges, but realizing that potential depends on pragmatic alignment between manufacturing capabilities, regulatory navigation, and the operational realities of diverse end users. Stakeholders that invest in flexible manufacturing, robust surveillance, and strategic partnerships will be best positioned to convert scientific promise into durable herd health outcomes.
Moving forward, the combination of regional manufacturing resilience, outcome-focused communication to producers, and rigorous post-market evidence will differentiate successful programs. Firms that effectively integrate these elements can expect greater acceptance by veterinarians and producers, stronger relationships with regulators, and a more resilient commercial footprint in the face of trade and logistical disruptions. The collective imperative is to translate innovation into reliable, accessible vaccines that sustain productivity, animal welfare, and public trust in livestock health systems.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
183 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Advanced mRNA vaccine platforms gaining traction for rapid porcine disease control
- 5.2. Integration of novel nanoparticle adjuvants to enhance porcine influenza vaccine efficacy
- 5.3. Government funding initiatives accelerating African swine fever vaccine commercialization efforts
- 5.4. Strategic partnerships between biotech startups and major animal health companies to co-develop next-generation porcine vaccines
- 5.5. Adoption of digital diagnostic tools for real-time monitoring of porcine herd immune status before vaccination
- 5.6. Rising demand for broad-spectrum multivalent vaccines targeting multiple swine respiratory pathogens in growing herds
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Porcine Vaccines Market, by Vaccine Type
- 8.1. Inactivated
- 8.1.1. Split Virus
- 8.1.2. Subcellular
- 8.1.3. Whole Virus
- 8.2. Live Attenuated
- 8.2.1. Heterologous
- 8.2.2. Homologous
- 8.3. MRNA
- 8.3.1. Non Amplifying MRNA
- 8.3.2. Self Amplifying MRNA
- 8.4. Subunit
- 8.4.1. Polysaccharide Subunit
- 8.4.2. Protein Subunit
- 8.5. Virus Vectored
- 8.5.1. Adenovirus Vector
- 8.5.2. Poxvirus Vector
- 9. Porcine Vaccines Market, by Disease Indication
- 9.1. Classical Swine Fever
- 9.2. Erysipelas
- 9.3. Porcine Reproductive And Respiratory Syndrome
- 9.4. Swine Influenza
- 10. Porcine Vaccines Market, by End User
- 10.1. Commercial Farm
- 10.2. Research Institute
- 10.3. Smallholder Farm
- 10.4. Veterinary Hospital
- 11. Porcine Vaccines Market, by Route Of Administration
- 11.1. Intradermal
- 11.2. Intramuscular
- 11.3. Intranasal
- 11.4. Oral
- 11.5. Subcutaneous
- 12. Porcine Vaccines Market, by Technology
- 12.1. Conventional
- 12.1.1. Attenuated Live
- 12.1.2. Killed Whole
- 12.2. DNA
- 12.3. Recombinant
- 12.3.1. Bacteria Expressed
- 12.3.2. Insect Cell Expressed
- 12.3.3. Yeast Expressed
- 12.4. RNA
- 12.5. VLP
- 13. Porcine Vaccines Market, by Dosage Form
- 13.1. Emulsion
- 13.2. Liquid
- 13.3. Lyophilized
- 14. Porcine Vaccines Market, by Region
- 14.1. Americas
- 14.1.1. North America
- 14.1.2. Latin America
- 14.2. Europe, Middle East & Africa
- 14.2.1. Europe
- 14.2.2. Middle East
- 14.2.3. Africa
- 14.3. Asia-Pacific
- 15. Porcine Vaccines Market, by Group
- 15.1. ASEAN
- 15.2. GCC
- 15.3. European Union
- 15.4. BRICS
- 15.5. G7
- 15.6. NATO
- 16. Porcine Vaccines Market, by Country
- 16.1. United States
- 16.2. Canada
- 16.3. Mexico
- 16.4. Brazil
- 16.5. United Kingdom
- 16.6. Germany
- 16.7. France
- 16.8. Russia
- 16.9. Italy
- 16.10. Spain
- 16.11. China
- 16.12. India
- 16.13. Japan
- 16.14. Australia
- 16.15. South Korea
- 17. Competitive Landscape
- 17.1. Market Share Analysis, 2024
- 17.2. FPNV Positioning Matrix, 2024
- 17.3. Competitive Analysis
- 17.3.1. Zoetis Inc.
- 17.3.2. Merck & Co., Inc.
- 17.3.3. Boehringer Ingelheim International GmbH
- 17.3.4. Elanco Animal Health Incorporated
- 17.3.5. Ceva Santé Animale S.A.
- 17.3.6. Hipra, S.A.
- 17.3.7. Pharmgate Animal Health, LLC
- 17.3.8. Indian Immunologicals Ltd.
- 17.3.9. Kyoritsu Seiyaku Corporation
- 17.3.10. Bimeda Holdings PLC
- 17.3.11. Vaxxinova International BV
- 17.3.12. Jinyu Bio-Technology Co., Ltd.
- 17.3.13. Chengdu Tianbang Biological Products Co., Ltd.
- 17.3.14. Qilu Animal Health Products Co., Ltd.
- 17.3.15. Chopper Animal Health Co., Ltd.
- 17.3.16. Phibro Animal Health Corporation
- 17.3.17. Venkateshwara Hatcheries Pvt. Ltd.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
